We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin D for COVID-19 Trial (VIVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04536298
Recruitment Status : Active, not recruiting
First Posted : September 2, 2020
Last Update Posted : July 12, 2022
Sponsor:
Collaborators:
Harvard Medical School (HMS and HSDM)
Harvard School of Public Health (HSPH)
Fenway Health and Beth Israel Deaconess Medical Center
Tishcon Corporation
Takeda
Quest Diagnostics-Nichols Insitute
Laboratory Corporation of America
Trialfacts
Karolinska Institutet
Philanthropic donations
Information provided by (Responsible Party):
JoAnn E. Manson, MD, Brigham and Women's Hospital

Brief Summary:
The Vitamin D for COVID-19 Trial (VIVID) is a randomized, placebo-controlled clinical trial in 2024 men and women from across the U.S. and Mongolia to investigate whether taking a daily dietary supplement of vitamin D vs. placebo for 4 weeks reduces the rate of seeking healthcare for symptoms or concerns related to COVID-19 in participants recently diagnosed with COVID-19, and reduces the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in household contacts of individuals with newly diagnosed COVID-19.

Condition or disease Intervention/treatment Phase
COVID-19 Dietary Supplement: vitamin D Dietary Supplement: Placebo Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2024 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Cluster-Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vitamin D3 Supplementation to Reduce Disease Severity in Persons With Newly Diagnosed COVID-19 Infection and to Prevent Infection in Household Members
Actual Study Start Date : December 28, 2020
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : September 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Vitamin D
Daily vitamin D3 (9600 IU/day on days 1 and 2; 3200 IU/day on days 3 through 28)
Dietary Supplement: vitamin D
Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28
Other Names:
  • vitamin D3
  • cholecalciferol

Placebo Comparator: Placebo
Placebo
Dietary Supplement: Placebo
Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28




Primary Outcome Measures :
  1. Rate of seeking healthcare visits (including hospitalizations, emergency room visits, or ambulatory or virtual clinician visits) for symptoms or concerns related to COVID-19 or deaths in participants newly diagnosed with COVID-19 (index cases) [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Rate of in-person healthcare visits related to COVID-19 infection among index cases [ Time Frame: 4 weeks ]
  2. Disease symptom score in index cases [ Time Frame: 4 weeks ]
    Area under curve (AUC) of weekly self-reported symptom score (summed across all symptoms) through week 4

  3. Disease severity in index cases [ Time Frame: 4 weeks ]
    Self-report of at least one severe symptom

  4. Time to seeking healthcare (including hospitalizations, emergency room visits, or ambulatory or other clinician visits) or death in index cases [ Time Frame: 4 weeks ]
  5. SARS-CoV-2 infection in close household contacts [ Time Frame: 4 weeks ]
    Self-report of positive test

  6. Long COVID symptoms in index cases [ Time Frame: 8 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion/exclusion criteria for INDEX CASES:

Inclusion criteria

  1. Adults aged 18 years or older who are newly diagnosed with COVID-19 infection within 7 days of testing.
  2. Ability and willingness to understand and provide informed consent.

Exclusion criteria

  1. Known current pregnancy.
  2. Current hospitalization.
  3. Unable to complete online questionnaires or adhere to study requirements.
  4. Consume more than 1000 IU per day of vitamin D from all supplemental sources combined (individual vitamin D supplements, calcium plus vitamin D supplements, medications with vitamin D [e.g., Fosamax Plus D], and multivitamins) in the past 4 weeks.
  5. Use of prescription vitamin D treatments (Calcitriol [Rocaltrol, Calcitrol, Vectical, Calcijex] or Paricalcitol [Zemplar]).
  6. Consume supplements with more than 1200 mg calcium per day.
  7. Known diagnosis of hypercalcemia or a condition associated with vitamin D hypersensitivity.
  8. Prior diagnosis of cancer *AND* currently undergoing radiation, chemotherapy, or immunotherapy.
  9. Kidney failure or dialysis; severe liver disease or cirrhosis.
  10. Any parathyroid conditions.
  11. Use of medications for seizures or epilepsy. Examples: Carbamazepine (Carbatrol, Tegretol), Phenytoin (Dilantin, Phenytek), Valproic acid (Depakene), Oxcarbazepine (Oxtellar, Trileptal), Phenobarbital, Topiramate (Topamax).
  12. Use of digoxin.
  13. Inability to receive an overnight express mail shipment of study pills at a home address.
  14. Participation in other COVID-19 trials.

Inclusion/exclusion criteria for HOUSEHOLD CONTACTS:

Inclusion criteria:

  1. Persons aged 18 years or older who live in the same household with an index individual and have been identified as the closest household contact within the same household (limited to 1 per household).
  2. Persons aged 18 years or older who live in household with someone who tested positive for COVID-19 within past 7 days but not participating in VIVID.
  3. Ability and willingness to understand and provide informed consent.

Exclusion criteria:

  1. Known current pregnancy.
  2. History of SARS-CoV-2 infection.
  3. Receipt of a SARS-CoV-2 vaccination or monoclonal antibody.
  4. Unable to complete online questionnaires or adhere to study requirements.
  5. Consume more than 1000 IU per day of vitamin D from all supplemental sources combined (individual vitamin D supplements, calcium plus vitamin D supplements, medications with vitamin D [e.g., Fosamax Plus D], and multivitamins) in the past 4 weeks.
  6. Use of prescription vitamin D treatments (Calcitriol [Rocaltrol, Calcitrol, Vectical, Calcijex] or Paricalcitol [Zemplar]).
  7. Consume supplements with more than 1200 mg calcium per day.
  8. Known diagnosis of hypercalcemia or a condition associated with vitamin D hypersensitivity.
  9. Prior diagnosis of cancer *AND* currently undergoing radiation, chemotherapy, or immunotherapy.
  10. Kidney failure or dialysis; severe liver disease or cirrhosis.
  11. Any parathyroid condition.
  12. Use of medications for seizures or epilepsy. Examples: Carbamazepine (Carbatrol, Tegretol), Phenytoin (Dilantin, Phenytek), Valproic acid (Depakene), Oxcarbazepine (Oxtellar, Trileptal), Phenobarbital, Topiramate (Topamax).
  13. Use of digoxin.
  14. Inability to receive an overnight express mail shipment of study pills at a home address.
  15. Participation in other COVID-19 trials.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04536298


Locations
Layout table for location information
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Brigham and Women's Hospital
Harvard Medical School (HMS and HSDM)
Harvard School of Public Health (HSPH)
Fenway Health and Beth Israel Deaconess Medical Center
Tishcon Corporation
Takeda
Quest Diagnostics-Nichols Insitute
Laboratory Corporation of America
Trialfacts
Karolinska Institutet
Philanthropic donations
Investigators
Layout table for investigator information
Principal Investigator: JoAnn E Manson, MD, DrPH Brigham and Women's Hospital
Principal Investigator: Rui Wang, PhD Harvard Medical School (HMS and HSDM)
Principal Investigator: Davaasambuu Ganmaa, PhD Harvard School of Public Health (HSPH)
Publications:
Layout table for additonal information
Responsible Party: JoAnn E. Manson, MD, Professor of Medicine, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT04536298    
Other Study ID Numbers: 2020P002815
First Posted: September 2, 2020    Key Record Dates
Last Update Posted: July 12, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Details will be provided at a later date.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by JoAnn E. Manson, MD, Brigham and Women's Hospital:
COVID-19
SARS-CoV-2 infection
coronavirus
vitamin D
hospitalization
death
disease severity
treatment
prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Vitamin D
Ergocalciferols
Cholecalciferol
Vitamins
Micronutrients
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents